CN103958521B - 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途 - Google Patents
嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途 Download PDFInfo
- Publication number
- CN103958521B CN103958521B CN201280051684.7A CN201280051684A CN103958521B CN 103958521 B CN103958521 B CN 103958521B CN 201280051684 A CN201280051684 A CN 201280051684A CN 103958521 B CN103958521 B CN 103958521B
- Authority
- CN
- China
- Prior art keywords
- methyl
- amino
- pyrimidin
- thieno
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 O=C(*OCc1ccccc1)c1cc(CCC=C2)c2cn1 Chemical compound O=C(*OCc1ccccc1)c1cc(CCC=C2)c2cn1 0.000 description 10
- JEVIMALQKNFGPL-UHFFFAOYSA-N C=[SH-](Cc1cc(Br)ccc1)[N+](c1ccnc(C(NO)=O)c1)=O Chemical compound C=[SH-](Cc1cc(Br)ccc1)[N+](c1ccnc(C(NO)=O)c1)=O JEVIMALQKNFGPL-UHFFFAOYSA-N 0.000 description 1
- MBIKOPILZOZNQB-UHFFFAOYSA-N CC(C)(C)OC(N1CC(C2=CC(C(N(Cc3ccccc3)O)=O)=NCC2)=CCC1)=O Chemical compound CC(C)(C)OC(N1CC(C2=CC(C(N(Cc3ccccc3)O)=O)=NCC2)=CCC1)=O MBIKOPILZOZNQB-UHFFFAOYSA-N 0.000 description 1
- QHUQDSAOCGEXDN-UHFFFAOYSA-N CC(C)C1=CCCC(C2C=C(CCC3C)C3=CC2)=C1 Chemical compound CC(C)C1=CCCC(C2C=C(CCC3C)C3=CC2)=C1 QHUQDSAOCGEXDN-UHFFFAOYSA-N 0.000 description 1
- MSKJSMFQDLFBMP-UHFFFAOYSA-N CCNC1C=CC1O Chemical compound CCNC1C=CC1O MSKJSMFQDLFBMP-UHFFFAOYSA-N 0.000 description 1
- LGOHOQYCHHNOLU-UHFFFAOYSA-N CCONC(c1cc(N)ccn1)=O Chemical compound CCONC(c1cc(N)ccn1)=O LGOHOQYCHHNOLU-UHFFFAOYSA-N 0.000 description 1
- NHHQODYFAIOHDM-UHFFFAOYSA-O CN(CC1)CC=C1c1ccnc(C([NH2+]CC2C=CC=CC2)=O)c1 Chemical compound CN(CC1)CC=C1c1ccnc(C([NH2+]CC2C=CC=CC2)=O)c1 NHHQODYFAIOHDM-UHFFFAOYSA-O 0.000 description 1
- RYNRXEQQQRQHCM-UHFFFAOYSA-N Cc1c(-c(cc2)cc(C#N)c2F)[s]c(N=C(N)N2)c1C2=[U] Chemical compound Cc1c(-c(cc2)cc(C#N)c2F)[s]c(N=C(N)N2)c1C2=[U] RYNRXEQQQRQHCM-UHFFFAOYSA-N 0.000 description 1
- OHMQWSKTCQCCIM-UHFFFAOYSA-N Cc1c(-c2cc(CN(C)C)ccc2F)[s]c(N=C(N)N2)c1C2=O Chemical compound Cc1c(-c2cc(CN(C)C)ccc2F)[s]c(N=C(N)N2)c1C2=O OHMQWSKTCQCCIM-UHFFFAOYSA-N 0.000 description 1
- AXSCSMJQPHBJSA-UHFFFAOYSA-N Cc1c(C(C(F)=N2)=CCC2F)[s]c(N=C(N)N2)c1C2=O Chemical compound Cc1c(C(C(F)=N2)=CCC2F)[s]c(N=C(N)N2)c1C2=O AXSCSMJQPHBJSA-UHFFFAOYSA-N 0.000 description 1
- BKWZPBOCDBAURK-UHFFFAOYSA-N N=C1CCC(c2ccnc(C(N(Cc3ccccc3)O)=O)c2)=CCCC1 Chemical compound N=C1CCC(c2ccnc(C(N(Cc3ccccc3)O)=O)c2)=CCCC1 BKWZPBOCDBAURK-UHFFFAOYSA-N 0.000 description 1
- JBCBUORNAMFOTB-UHFFFAOYSA-N ON(CCCc1ccccc1)C(c1cc2ccccc2cn1)=O Chemical compound ON(CCCc1ccccc1)C(c1cc2ccccc2cn1)=O JBCBUORNAMFOTB-UHFFFAOYSA-N 0.000 description 1
- JXQHRBGKRVWGKR-UHFFFAOYSA-N ON(Cc1ccccc1)C(c1cc(NS(Cc2cccc(F)c2)(=O)=O)ccn1)=O Chemical compound ON(Cc1ccccc1)C(c1cc(NS(Cc2cccc(F)c2)(=O)=O)ccn1)=O JXQHRBGKRVWGKR-UHFFFAOYSA-N 0.000 description 1
- KKDHFTRWRJHPSK-UHFFFAOYSA-N ON(Cc1ccccc1)C(c1cc(NS(Cc2ccccc2)(=O)=O)ccn1)=O Chemical compound ON(Cc1ccccc1)C(c1cc(NS(Cc2ccccc2)(=O)=O)ccn1)=O KKDHFTRWRJHPSK-UHFFFAOYSA-N 0.000 description 1
- WTUQGAGSKXQSBE-UHFFFAOYSA-N ONC(c1cc([N+]([SH-](Cc2cc(C(F)(F)F)ccc2)=O)=O)ccn1)=O Chemical compound ONC(c1cc([N+]([SH-](Cc2cc(C(F)(F)F)ccc2)=O)=O)ccn1)=O WTUQGAGSKXQSBE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550057P | 2011-10-21 | 2011-10-21 | |
| US61/550,057 | 2011-10-21 | ||
| PCT/EP2012/070760 WO2013057253A1 (en) | 2011-10-21 | 2012-10-19 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103958521A CN103958521A (zh) | 2014-07-30 |
| CN103958521B true CN103958521B (zh) | 2016-10-19 |
Family
ID=47189887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280051684.7A Expired - Fee Related CN103958521B (zh) | 2011-10-21 | 2012-10-19 | 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130102601A1 (https=) |
| EP (1) | EP2794616B1 (https=) |
| JP (1) | JP6033873B2 (https=) |
| KR (1) | KR20140097197A (https=) |
| CN (1) | CN103958521B (https=) |
| BR (1) | BR112014008412A2 (https=) |
| CA (1) | CA2852843A1 (https=) |
| ES (1) | ES2589459T3 (https=) |
| MX (1) | MX342176B (https=) |
| RU (1) | RU2014120477A (https=) |
| WO (1) | WO2013057253A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016005330A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| WO2016033150A1 (en) * | 2014-08-28 | 2016-03-03 | X-Chem, Inc. | Soluble epoxide hydrolase inhibitors and uses thereof |
| WO2016133888A1 (en) * | 2015-02-16 | 2016-08-25 | Biota Pharmaceuticals, Inc. | Compounds for treating respiratory syncytial virus infections |
| BR112017022550B1 (pt) | 2015-04-28 | 2021-02-23 | Shionogi & Co., Ltd | derivados policíclicos de piridona substituída |
| US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| AU2016374416A1 (en) * | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| EP3478671B1 (en) | 2016-06-29 | 2020-05-13 | H. Hoffnabb-La Roche Ag | Pyridazinone-based broad spectrum anti-influenza inhibitors |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| MY200629A (en) | 2017-08-01 | 2024-01-06 | Theravance Biopharma R&D Ip Llc | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2021207530A1 (en) * | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2022194800A1 (en) * | 2021-03-17 | 2022-09-22 | F. Hoffmann-La Roche Ag | New thienopyrimidinone derivatives |
| US11932656B1 (en) | 2023-10-06 | 2024-03-19 | King Faisal University | Thieno[2,3-d]pyrimidines as COX-2 inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009062258A1 (en) * | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
| WO2011000566A2 (en) * | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EP1485390B1 (en) * | 2002-03-07 | 2008-10-08 | F. Hoffman-la Roche AG | Bicyclic pyridine and pyrimidine p38 kinase inhibitors |
| CN101014572B (zh) | 2004-09-15 | 2011-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物 |
| ES2665277T3 (es) | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
-
2012
- 2012-10-18 US US13/655,418 patent/US20130102601A1/en not_active Abandoned
- 2012-10-19 CA CA2852843A patent/CA2852843A1/en not_active Abandoned
- 2012-10-19 KR KR1020147013721A patent/KR20140097197A/ko not_active Withdrawn
- 2012-10-19 JP JP2014536253A patent/JP6033873B2/ja not_active Expired - Fee Related
- 2012-10-19 MX MX2014003801A patent/MX342176B/es active IP Right Grant
- 2012-10-19 CN CN201280051684.7A patent/CN103958521B/zh not_active Expired - Fee Related
- 2012-10-19 RU RU2014120477/04A patent/RU2014120477A/ru not_active Application Discontinuation
- 2012-10-19 EP EP12787384.2A patent/EP2794616B1/en not_active Not-in-force
- 2012-10-19 WO PCT/EP2012/070760 patent/WO2013057253A1/en not_active Ceased
- 2012-10-19 ES ES12787384.2T patent/ES2589459T3/es active Active
- 2012-10-19 BR BR112014008412A patent/BR112014008412A2/pt not_active IP Right Cessation
-
2016
- 2016-06-15 US US15/182,705 patent/US20160376286A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009062258A1 (en) * | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
| WO2011000566A2 (en) * | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
Non-Patent Citations (2)
| Title |
|---|
| Identification of N-hydroxamic acid and N-hydroxyimide compounds that inhibit the influenza virus polymerase;C. Cianc，等;《Antiviral Chemistry & Chemotherapy》;19961231;第7卷(第6期);第353-360页 * |
| Synthesis of Classical and Nonclassical 2-Amino-4-oxo-6-benzylthieno[2,3-d]pyrimidines as Potential Thymidylate Synthase Inhibitors;Aleem Gangjee，等;《J. Heterocyclic Chem.》;20041231;第41卷(第6期);第941-946页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2794616B1 (en) | 2016-06-29 |
| US20160376286A1 (en) | 2016-12-29 |
| CA2852843A1 (en) | 2013-04-25 |
| WO2013057253A1 (en) | 2013-04-25 |
| HK1199881A1 (en) | 2015-07-24 |
| US20130102601A1 (en) | 2013-04-25 |
| JP2014530838A (ja) | 2014-11-20 |
| RU2014120477A (ru) | 2015-11-27 |
| BR112014008412A2 (pt) | 2017-04-11 |
| CN103958521A (zh) | 2014-07-30 |
| MX342176B (es) | 2016-09-20 |
| MX2014003801A (es) | 2015-03-11 |
| KR20140097197A (ko) | 2014-08-06 |
| ES2589459T3 (es) | 2016-11-14 |
| JP6033873B2 (ja) | 2016-11-30 |
| EP2794616A1 (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103958521B (zh) | 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途 | |
| CN103958475B (zh) | 杂芳基异羟肟酸衍生物及其在治疗、减轻或预防病毒疾病中的用途 | |
| JP2015524457A (ja) | ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用 | |
| JP2015521189A (ja) | ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体 | |
| JP2015517555A (ja) | ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| US8952039B2 (en) | Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease | |
| US9505758B2 (en) | Substituted 1,5-naphthyridines as endonuclease inhibitors | |
| US20170081331A1 (en) | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease | |
| HK1199881B (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161019 Termination date: 20171019 |